

seen and followed closely in a single-practice, real-world situation that provides a representative picture of cancer patients in general. It defines the relative incidence and subtypes of multiple primaries among cancer patients of various ethnic groups as well as their impact on survival. It showed relatively consistent results, whether cancer was inclusive of all subtypes or limited to a certain stage of disease, and whether the study population was initially diagnosed over several decades or limited to a defined period of time.

Conclusion

In conclusion, patients with multiple primaries are usually of Caucasian ancestry, have less aggressive malignancies, present at earlier stages of disease, and frequently have a strong family history of similar malignancies. They tend to have cancers with indolent clinical behavior and longer overall survival, especially in those developing second malignancies more than 5 years after the initial primary diagnosis. For patients with three or more primaries, their survival has been similar to the projected life expectancy of the age-matched and sex matched normal population, even though they were treated less aggressively. The development of multiple primaries may possibly be related to genetic disorders of known or an unidentified nature. The higher frequency of cancer predisposition genes in Caucasians may well explain this increased frequency of multiple primaries. The possibility of multiple primary malignancies should always be considered during the treatment and follow-up of cancer patients, especially those of Caucasian ancestry and those having a strong family history of cancer. Due to the potential for long-term survival, more aggressive treatment may be warranted. For elderly and relatively asymptomatic cases having more than three primaries, a less aggressive approach to therapy may be adequate.

Acknowledgments

The author thanks Joseph Anigbogu, Kemi Azeez, Pratap Balusu, Glenn Bryant, Sreenivasa Chanamololu, Henry Gerad, Ravi Kamepalli, Abbas Khalil, Sarat Kuchipudi, Chaoyang Li, Oluremi Ojo, David Powell, and Abdullah Taja for patient referrals.

Disclosure

The author reports no conflicts of interest in this work.

References

1. Gursel B, Meydan D, Ozbek N, Ozdemir O, Odabas E. Multiple primary malignant neoplasms from the black sea region of Turkey. *J Int Med Res*. 2011;39(2):667–674.

2. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. *Cancer Epidemiol Biomarkers Prev*. 2007;16(3):566–571.
3. Soerjomataram I, Louwman WJ, de Vries E, Lemmens VE, Klokman WJ, Coebergh JW. Primary malignancy after primary female breast cancer in the South of The Netherlands, 1972–2001. *Breast Cancer Res Treat*. 2005;93(1):91–95.
4. Rosso S, De Angelis R, Ciccolallo L, et al. Multiple tumours in survival estimates. *Eur J Cancer*. 2009;45(6):1080–1094.
5. Friedrich RE. Primary and second primary cancer in 649 patients with malignancies of the maxillofacial region. *Anticancer Res*. 2007;27(4A):1805–1818.
6. Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. *Cancer Sci*. 2012;103(6):1111–1120.
7. Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. *Blood*. 2012;119(12):2731–2737.
8. Liu L, de Vries E, Louwman M, et al. Prevalence of multiple malignancies in The Netherlands in 2007. *Int J Cancer*. 2011;128(7):1659–1667.
9. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship – genetic susceptibility and second primary cancers: research strategies and recommendations. *J Natl Cancer Inst*. 2006;98(1):15–25.
10. Pages PB, Mordant P, Grand B, et al. History of multiple previous malignancies should not be a contraindication to the surgical resection of lung cancer. *Ann Thorac Surg*. 2013;95(3):1000–1005.
11. Bordin GM, Key CR, McQuade CE, Kutvirt DM, Hughes WB, Brylinski DA. Multiple primary cancers: relative risk in New Mexico's triethnic population. *Cancer*. 1977;40(Suppl 4):1793–1800.
12. Hajdu SI, Hajdu EO. Multiple primary malignant tumors. *J Am Geriatr Soc*. 1968;16(1):16–26.
13. Haddow AJ, Boyd JF. Multiple primary neoplasms in the Western Hospital Region, Scotland: a survey based on cancer registration data. *Scott Med J*. 1972;17(4):143–152.
14. Rosso S, Terracini L, Ricceri F, Zanetti R. Multiple primary tumours: incidence estimation in the presence of competing risks. *Popul Health Metr*. 2009;7:5.
15. Berge T, Cederqvist L, Schonebeck J. Multiple primary malignant tumours. An autopsy study of a circumscribed population. *Acta Pathol Microbiol Scand*. 1969;76(2):171–183.
16. Salem A, Abu-Hijli R, Abdelrahman F, et al. Multiple primary malignancies: analysis of 23 patients with at least three tumors. *J Gastrointest Cancer*. 2012;43(3):437–443.
17. Watanabe S, Kodama T, Shimamoto Y, et al. Multiple primary cancers in 5,456 autopsy cases in the National Cancer Center of Japan. *J Natl Cancer Inst*. 1984;72(5):1021–1027.
18. Lee TK, Myers RT, Scharyj M, Marshall RB. Multiple primary malignant tumors (MPMT): study of 68 autopsy cases (1963–1980). *J Am Geriatr Soc*. 1982;30(12):744–753.
19. Panosetti E, Lubinski B, Mamelle G, Richard JM. Multiple synchronous and metachronous cancers of the upper aerodigestive tract: a nine-year study. *Laryngoscope*. 1989;99(12):1267–1273.
20. Weir HK, Johnson CJ, Thompson TD. The effect of multiple primary rules on population-based cancer survival. *Cancer Causes Control*. 2013;24(6):1231–1242.
21. Sankila R, Pukkala E, Teppo L. Risk of subsequent malignant neoplasms among 470,000 cancer patients in Finland, 1953–1991. *Int J Cancer*. 1995;60(4):464–470.
22. Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. *Methods Mol Biol*. 2009;471:85–105.
23. Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. *J Clin Oncol*. 2011;29(22):3056–3064.
24. Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF, Bardawil WA. Role of heredity in multiple primary cancer. *Cancer*. 1977;40(Suppl 4):1849–1854.